Growing Human Brains in Space
University of California Television (UCTV)
0:19 Alysson Muotri: I'll share a little bit of the work that we do in the lab,
0:23 basically sending brain tissues or brain organoids to space,
0:28 and there is a reason for that.
0:30 My lab focus on neurological conditions.
0:33 Most of them neurogenetic conditions such as autism.
0:37 You are born with autism.
0:40 You don't get autism after you are born.
0:43 Everything happens in uterus, inside the uterus,
0:48 and this inaccessibility of the brain tissue is one
0:51 of the things that makes the sign so hard.
0:54 It's different from cancer, from heart, from blood, where you can have biopsies.
1:00 You can see what's happening.
1:01 In the brain, it starts in uterus and keeps inside that is core to your life.
1:08 Really hard to study.
1:10 Despite the fact that we know
1:12 that these conditions have a strong genetic factor,
1:16 we don't know exactly how the genes plays into behavior and neuroscience.
1:20 The interface between the genetics and neurobiology,
1:24 that's exactly where my lab is.
1:27 We start developing tools to actually create
1:31 better models to understand the human brain.
1:34 As I mentioned, because this always starts in uterus so I turn into stem cells.
1:40 That's when the brain tissue start to become what we have today in our heads.
1:46 It always start with stem cells.
1:48 I was inspired by the first observation that stem cells when growing suspension
1:54 and neutralize can form these clusters
1:56 of cells that we now call brain organoids.
2:00 Over the years, my lab have been improving
2:03 these protocols to create something that is more robust, cheaper,
2:07 easy accessibility, and also a protocol that produces neurons
2:13 that can fire and connect to each other forming networks.
2:17 This is an example of what we call a semi-guided brain organoid where we
2:21 transiently expose progenitor cells to specific factors
2:26 that guide the cells towards the cortical tissue.
2:28 It's a simple protocol where you neuralize the pluripotent stem cells.
2:33 Again, in suspension induce the proliferation
2:35 of the precursor cells, and afterwards,
2:38 you just withdraw these factors and the cells will mature over time,
2:41 forming these spheres that contains about five million cells,
2:45 2.5 million neurons in each one of them.
2:48 If you've never seen one, this is how we grow them in these six well dishes.
2:53 Each one of these white dot is the beginning of a brain
2:56 organoid that will grow up to 2.5 centimeter in diameter.
3:00 The cool thing about these organoids is
3:02 that you can measure the electrical activity,
3:05 and we have been following how these networks rearrange and connect over a year,
3:11 and this is more or less what we learned that it
3:13 takes about two months for them to have a robust electrical activity.
3:18 Before that, you can see neurons firing,
3:20 but they are not connecting to each other.
3:22 They're just firing in a random fashion.
3:25 After two months, they start to get organized and start
3:28 to form some circuitries that might generate what we call neural oscillation.
3:33 These neural oscillations will develop through the next month or two,
3:38 and will become quite robust and stereotype.
3:42 After that, these oscillations will become more complex over time,
3:47 and this is all due to the emergency
3:49 of specific cell types in this population such
3:52 as astrocytes that helps with the synaptogenesis
3:55 or inhibitory neurons that help to modulate this network.
4:00 The cool part of this model is that it
4:02 recapitulates the early stages of neurodevelopment quite well.
4:06 Even the timing it's quite well reproduced in our dishes.
4:13 It takes about nine months for the human
4:16 brain to start showing these complex neural oscillation.
4:21 The model is perfect to study conditions such as autism.
4:25 The problem is that we don't want to just focus on the preembryonic stages,
4:31 but we want to also understand what happens
4:33 when our brains are 1, 2, 10, 9-years-old.
4:36 We start getting into the age factor of the model,
4:41 which is not currently possible.
4:43 I was looking to ways of doing that.
4:46 How can I speed up?
4:48 How can I accelerate neurodevelopment in the lab,
4:51 and that's when I came across some of the NASA literature suggesting that cells
4:56 from the astronauts returning from the space
5:00 actually show signs of accelerated senescence,
5:03 something that might be seen as an accelerated aging,
5:06 and even more importantly, signs of cognitive decline has also been reported,
5:12 and this cognitive decline cannot be fully
5:16 restored even six months after the flights.
5:19 This is also a concern for long flights into space,
5:24 but we can actually think about leveraging
5:27 this phenomenon here to earth to understand age-related conditions.
5:32 Starting in 2019, we actually have several missions to the International Space
5:38 Station by sending brain organoids
5:40 in an autonomous platform together with Space Tango,
5:45 our implementational partners.
5:47 These organoids have specific payloads that changes the media,
5:52 keep them alive in a similar way as we would do it here.
5:55 Because these platforms are quite autonomous,
5:58 the astronaut doesn't need to do too much.
6:02 Basically plug these boxes inside the cabinets in there,
6:07 and then we have immediately access to the experiments inside.
6:11 What did we learn with these experiments?
6:14 Most of the experiments are kept
6:17 at the International Space Station for about 30 days.
6:21 Upon their return, what we learned was that some
6:25 of the cells show signs of cellulated aging or extreme maturation,
6:31 and this is seen in the transcriptomics.
6:34 This is just comparing space and ground controls.
6:37 Several molecular pathways related to senescence is also highlighted.
6:43 On the proteomic side, this was done by Lynn and Paolo at the Ice Core,
6:48 where they compare the overall proteomic changes
6:51 that happens after these 30 days in space,
6:54 reaching a specific age of about 10-12 years on average.
7:00 Thirty days in space when the cells return,
7:03 they'll have a proteomic profile of a neuron or a brain
7:07 cell that is equivalent of a 10, 12-year-old person.
7:11 Moreover, on the proteomics,
7:13 we can also take advantage of single cell proteomics to understand
7:17 different cell populations and what happens inside each one of these cells.
7:22 So complicated is lies, and I believe Aline might detail this more.
7:26 But again, I mean, we see several
7:29 molecular pathways that are age related conditions,
7:33 increasing some pathoys that are quite interesting,
7:36 for example, the derepression of retro elements.
7:39 These are endogenous retrovirus inside the genome.
7:43 But also mitochondria is affected.
7:45 Oncogenes, your telomeres are affected.
7:49 Several of these molecular pathways that we see only in more adult,
7:55 older postmortem tissues.
7:57 Even more importantly,
7:58 once these cells return or the brain organoids return to earth,
8:03 we can actually measure the electrical activity
8:06 by placing them on top of multi electrode array.
8:09 What we are learning is that over time, different from the ground control,
8:14 there is indications that the networks start to get fragmented.
8:20 Instead of starting getting more connected as you would expect,
8:24 if a linear development here on Earth, we see fragmentation of the network,
8:30 something that will be related to dementia or an Alzheimer's network.
8:36 Is there any useful of all this information?
8:39 In one of those missions,
8:41 we start sending patient derived brain organoids to space,
8:44 and we start with Rett syndrome is a neurological
8:47 condition that I have been studying for a while.
8:50 It's quite severe.
8:51 The kids develop quite normal for the first 18 months.
8:55 You even didn't notice that there is a problem there.
8:58 But after that, there is a decline
9:01 and the kids start losing their motor abilities, their verbal capabilities,
9:06 basically all their skills,
9:08 and end up in a wheelchair for the rest of their life.
9:12 What happens in these 18 months that the system their brains crash.
9:17 We don't have good models for that.
9:19 I told you that the brain
9:21 organoid model just recapitulated the pre-embryonic phase,
9:24 and the mouse model doesn't survive that long.
9:27 We really don't know what happens to the brain when it reached that stage.
9:32 By sending Rett syndrome brain organoids, we learned something new.
9:35 We learned that brain cells, specifically glia cells or astrocytes
9:40 from the organoids accumulate the endogenous
9:43 retrovirus that I mentioned to you that has been related to aging.
9:47 The accumulation of the retrovirus leads to an increase in inflammation.
9:52 Rett syndrome was never proposed to be an inflammatory condition,
9:56 so it's only in this model that we could
9:58 actually see elevation of certain cytokines such as IL-6.
10:03 If the accumulation of endogenous retrovirus is related to aging,
10:08 there's tons of evidence in the literature
10:11 indicating that these specifically line elements
10:15 could actually accumulate in the cytoplasm
10:18 and trigger some of these pro-inflammatory pathways.
10:22 If we were able to target that using reverse-transcriptase inhibitors,
10:27 for example, antiretroviral drugs, perhaps we could eliminate the inflammation
10:33 and help with the brains with Rett syndrome.
10:36 Sounds weird treating a neurological condition with an antiretroviral,
10:41 HIV drugs that are already FDA approved, cheap drugs.
10:45 I mean, would that be possible?
10:47 Then we turn back into our preclinical models
10:52 here on Earth both mouse and human models.
10:57 I'll show you just one example of the mouse models here,
11:03 where we treat the animals just
11:05 before they die with reverse-transcriptase inhibitors,
11:08 and the animals increase the survival
11:11 and start to reacquiring their motor skills again.
11:14 This was, to the best of our knowledge,
11:18 something that was never seen before for this specific model for Rett syndrome.
11:24 Not only the behavior,
11:27 but we actually see changes in the morphology of the neurons.
11:30 They recapitulate the spine density,
11:32 even the size of the neurons could be restored.
11:35 That was enough for the FDA to approve the clinical
11:40 trial for Rett syndrome and we start treating these patients.
11:45 Hopefully, in six months from now, we're going to know if antiretrovirals are
11:49 useful for the treatment of Rett syndrome.
11:52 But what about age related conditions more towards the end of your life,
11:58 such as Alzheimer's and dementia?
12:00 This is a big market, and we also wanted to focus on that.
12:03 We have a postdoc in the lab that is focusing on Alzheimer's.
12:08 That's Natalia Sherman.
12:09 She's been sending brain organoids derived
12:12 from Alzheimer's to the space station.
12:14 Again, I will not give you too much details here,
12:17 but just to say that there are specific pathways,
12:20 especially related to the synopsis that seems
12:23 to be affected in Alzheimer's disease.
12:25 We are still trying to understand how these networks are affected.
12:29 But nonetheless, having a model
12:31 for Alzheimer's is really helpful because, again,
12:33 I mean, where would you get older human neurons to test potential treatments?
12:39 There is no model for Alzheimer's.
12:42 We think that this might be like
12:43 a value opportunity for us to test potential therapeutics.
12:47 I decided to team up with the largest pharmaceutic in the world,
12:53 which is my friends in the Amazon.
12:57 In the Amazon, there is about 300,000 species in there,
13:01 and certain plants do contain neuroactives
13:04 that has never been studied by modern science.
13:07 The idea was team up with the original tribes and search
13:14 for their ancestral knowledge to find what are the plants.
13:18 I'll play a quick video that illustrate more or less how this is done.
13:22 We start by the identification of these plants.
13:26 Again, in collaboration with these original tribes,
13:29 they point us to the plants that might be neuroprotective for the human brain.
13:35 They have been using this for thousands of years, actually.
13:41 Some of these plants are not so easy to get.
13:43 They are embedded inside of the Amazon.
13:46 To do that, we create a specific AI to inside
13:51 a little robot that contains the ancestral knowledge of the Shamans.
13:55 It's a visual system.
13:57 These little robots, you're going to see in a moment,
14:00 can actually fly through the forest and identify the specific
14:05 plants that we can send like someone to collect.
14:08 Someone from the tribes will go there, collect the plants,
14:11 replant more, and bring it back to the lab.
14:14 Once in the lab, we can isolate the extract
14:18 and using a several AI type of pipeline,
14:21 which would take thousands of years to do it five years ago,
14:26 now we can do it in a week.
14:28 We can actually point to specific molecules
14:31 that can bind to specific neuronal receptors.
14:33 We are scoring these molecules.
14:36 This would be the first candidate to travel to space
14:40 to actually be tested directly into brain organoids over there.
14:45 Once we bring the cells back,
14:47 the ones that has been exposed to certain of these molecules,
14:51 if they show reversal of the phenotypes, those are going to be strong
14:57 candidates for potential therapeutics for Alzheimer's,
15:00 dementia, and other neurodegenerative disorders.
15:04 We are also working better ways to visualize the activity of the neurons,
15:09 working with fluorescent markers as well as pathophysiology
15:13 that can be done actually in space.
15:17 We have real time capabilities through the ascending,
15:22 the time in space, and also descending.
15:25 That would be a game changer for us right now,
15:27 we put the organoids in a box, goes to the space, comes back.
15:31 We don't know what happens in between.
15:33 We just know before and after.
15:35 But this time would allow us to actually
15:38 follow the entire trajectory of these organoids.
15:42 I'm finishing here.
15:44 These are basically my take home messages.
15:47 We think that growing these brain organoids in space can
15:51 teach us about the impact of space into human cognition.
15:57 We can accelerate aging and use this as a model
16:01 for aging here on Earth, not only aging,
16:04 but rejuvenation and treatments and can be used to test novel neuroprotective
16:10 molecules or compounds either from Pharma who may have them on their shelves,
16:16 as well as new drugs that has never been discovered before.
16:20 I'll end here by thanking the members of Ice
16:25 Core that participates on that, several of the funding agencies.
16:29 Thank you.
16:30 [APPLAUSE] Speaker 1: Can you tell us a little bit more about
16:35 your clinical trial that you're doing and where that started?
16:39 Alysson Muotri: Yeah.
16:40 Right now because it's FDA approved drug,
16:43 the clinical trial was immediately approved by the FDA.
16:47 We also approved that in Brazil.
16:49 We are starting there in Brazil with a pilot
16:53 experiment that is going to be, I believe,
16:55 13 kids, different ages, and half of them would take placebo,
17:01 half of them would take the real drug.
17:03 There is a doctor that specialize in the milestones of these patients to see
17:09 if we can have either a slow
17:12 progression through these milestones or any reversal.
17:16 Speaker 1: We get to see each other all the time,
17:18 and yet I have so many questions.
17:20 Would it be possible to do some of the preliminary extraction and API,
17:24 active pharmaceutical ingredient development in Brazil closer
17:27 to where the sources for these new compounds?
17:31 Alysson Muotri: Oh, for the new compounds.
17:33 Yeah, absolutely.
17:34 This is something we're thinking about.
17:37 It will depend on the molecule.
17:40 As you know, some of the molecules might be hard to synthesize.
17:43 Speaker 2: Truly inspiring.
17:46 I'm guessing a lot of those compounds that you're screening can
17:50 relate to a lot of neurodegeneration that is related or not,
17:55 maybe to DNA damage and things like that.
17:57 Have you considered also,
18:00 in your screening an AI base to extend it not only to neuroreceptors,
18:06 but maybe other things that we know that maybe we can screen,
18:09 and there are so many people around us that can look,
18:12 oh, that can be actually a super cool candidate.
18:15 Alysson Muotri: Yeah.
18:16 You are absolutely right.
18:17 That's the ultimate goal is to create a catalog where this would be available.
18:22 People can mind that, can see if it works in other cell types.
18:26 Absolutely.
18:26 We are also working with not only isolated molecules, but extracts.
18:32 If we want to start with an extract, might be better chances to find something.
18:36 Then you funnel out a specific molecule.
18:40 Speaker 2: That's beautiful.
18:41 Thank you.
18:42 Speaker 3: I think connected to that, not
18:45 just other cell types or other diseases.
18:48 What about other plants, not just in Amazon, but other areas of the world?
18:53 Alysson Muotri: Yeah.
18:54 Once I start talking about that, other groups start
19:00 to reaching out to reproduce similar things with different ecosystems.
19:05 For example, the Saudis have the coral reefs that are bleaching,
19:11 and before it bleaches, they start collecting bacteria from them and create
19:15 a chemical library from the coral reefs.
19:18 That's another thing that is going to get extinct.
19:21 People will not be able to reproduce that.
19:24 But finally, I mean,
19:25 they save at least a part of that and could be used to screen as well.
19:30 Also, I started working with Bill Panico, who he's retired now,
19:34 but he was from scripts of oceanography here,
19:37 where he isolated bacteria from deep sea,
19:40 also contains lots of molecules that has never been studied before.
19:45 [MUSIC]